UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways

Frontiers in cardiovascular medicine, 2022-09, Vol.9, p.930797-930797

2022

Volltextzugriff (PDF)

Addressing Post-Acute COVID-19 Syndrome in Cancer Patients, from Visceral Obesity and Myosteatosis to Systemic Inflammation: Implications in Cardio-Onco-Metabolism

Biomedicines, 2024-07, Vol.12 (8), p.1650

2024

Volltextzugriff (PDF)

Screening and management of dyslipidemia in oncologic patients undergoing cardiotoxic therapies: results from an Italian survey

Cardio-oncology (London, England), 2023-08, Vol.9 (1), p.32-32, Article 32

2023

Volltextzugriff (PDF)

Women at heart: Introducing gender cardio-oncology

Frontiers in cardiovascular medicine, 2022-11, Vol.9, p.974123-974123

2022

Volltextzugriff (PDF)

Corrigendum: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways

Frontiers in cardiovascular medicine, 2023-01, Vol.10, p.1129873-1129873

2023

Volltextzugriff (PDF)

Case Series: Recovery of Chemotherapy-Related Acute Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable Cardioverter Defibrillator: A Novel Winning Combination in Cardio-Oncology

Frontiers in cardiovascular medicine, 2022-03, Vol.9, p.801143

2022

Volltextzugriff (PDF)

Portrait of Italian Cardio-Oncology: Results of a Nationwide Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Survey

Frontiers in cardiovascular medicine, 2021-06, Vol.8, p.677544-677544

2021

Volltextzugriff (PDF)

Corrigendum: Cardio-oncology in the COVID Era (Co & Co): The never-ending story

Frontiers in cardiovascular medicine, 2023-03, Vol.10, p.1169176-1169176

2023

Volltextzugriff (PDF)

Corrigendum: Portrait of Italian Cardio-Oncology: Results of a Nationwide Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Survey

Frontiers in cardiovascular medicine, 2022-05, Vol.9, p.920605-920605

2022

Volltextzugriff (PDF)

Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story

Frontiers in cardiovascular medicine, 2022, Vol.9, p.821193

2022

Volltextzugriff (PDF)

Corrigendum: Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story

Frontiers in cardiovascular medicine, 2022-05, Vol.9, p.903766-903766

2022

Volltextzugriff (PDF)

Arterial Thrombosis in Cancer: Spotlight on the Neglected Vessels

Anticancer research, 2019-09, Vol.39 (9), p.4619-4625

2019

Volltextzugriff (PDF)

DAPAGLIFLOZIN INCREASES PAMPK AND REDUCES MYOCARDIAL AND RENAL NF-KB EXPRESSION IN PRECLINICAL MODELS OF SHORT-TERM DOXORUBICIN CARDIOTOXICITY THROUGH MYDDOSOME AND INFLAMMASOME PATHWAYS: A HISTOLOGICAL STUDY

Journal of the American College of Cardiology, 2023-03, Vol.81 (8), p.2270-2270

2023

Volltextzugriff (PDF)

BERBERINE ASSOCIATED TO DAPAGLIFLOZIN EXERTS SIGNIFICANT CARDIOPROTECTIVE EFFECTS IN CARDIAC CELLS EXPOSED TO THE HER2-BLOKING AGENT TRASTUZUMAB THROUGH PAMPK ACTIVATION AND REDUCTION IN INTERLEUKIN-6 LEVELS

Journal of the American College of Cardiology, 2023-03, Vol.81 (8), p.2271-2271

2023

Volltextzugriff (PDF)

DAPAGLIFLOZIN REDUCES SYSTEMIC PCSK9 LEVELS IN PRECLINICAL MODELS OF SHORT-TERM DOXORUBICIN CARDIOTOXICITY THROUGH NLRP3 INFLAMMASOME/IL-1β: A FIRST EVIDENCE OF SGLT-2/PCSK9 CROSS-TALK IN CARDIONCOLOGY

Journal of the American College of Cardiology, 2023-03, Vol.81 (8), p.2269-2269

2023

Volltextzugriff (PDF)

Concepts in cardiac oncology

European heart journal supplements, 2020-11, Vol.22 (Suppl L), p.L19-L23

2020

Volltextzugriff (PDF)

Dapagliflozin associated to sacubitril/valsartan and relationship with cardioprotection in human cardiac cells exposed to doxorubicin and HER2-blocking agents through MyD88, NLRP3 mediated pathways

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.587-587

2022

Volltextzugriff (PDF)

Abstract 12406: Sglt2i Dapagliflozin Associated to Berberine Reduces Cardiac Cell Apoptosis and Necrosis During Exposure to Her-2 Blocking Agents Through Induction of Pampk and Reduction of Inflammasome, Il-6, Methylglyoxal and Leukotrienes-B4 Levels

Circulation (New York, N.Y.), 2022-11, Vol.146 (Suppl_1)

2022

Volltextzugriff (PDF)

Abstract 12402: Sacubitril-Valsartan Increases Pampk and Reduces Inflammasome, Myddosome, Il-6 and Galectin-3 Levels in Short-Term Doxorubicin-Treated Mice Improving Longitudinal Strain and Ejection Fraction

Circulation (New York, N.Y.), 2022-11, Vol.146 (Suppl_1)

2022

Volltextzugriff (PDF)

Abstract 12401: Short-term Pdl-1 and Ctla-4 Blocking Agent Therapy Reduces Myocardial Pampk and Il-10 Levels, Increases Vascular Nf-kb Expression and Serum Il-1 / Il-6 Levels

Circulation (New York, N.Y.), 2022-11, Vol.146 (Suppl_1)

2022

Volltextzugriff (PDF)

Abstract 10603: Dapagliflozin Increases Ampk, Reduces Fibrosis/Hypertrophy and Nlrp-3, Il-6 and Galectin-3 Levels in Short-Term Doxorubicin-Treated Mice Improving Cardiac Function

Circulation (New York, N.Y.), 2022-11, Vol.146 (Suppl_1)

2022

Volltextzugriff (PDF)

COMBINATORIAL IMMUNE CHECKPOINT BLOCKADE INCREASES MYOCARDIAL SECRETION OF H-FABP, NT-PRO-BNP, NLRP-3 INFLAMMASOME, INTERLEUKIN-1β AND INTERLEUKIN-6: BIOCHEMICAL IMPLICATIONS IN CARDIO-IMMUNO-ONCOLOGY

Journal of the American College of Cardiology, 2024-04, Vol.83 (13), p.2380-2380

2024

Volltextzugriff (PDF)

FRUCTOSE EXACERBATES ANTHRACYCLINE AND HER-2 BLOCKING AGENT MEDIATED CARDIOTOXICITY THROUGH NLRP3 AND MYD88 MEDIATED PATHWAYS: NEW ROLES OF SWEETENERS IN CARDIO-ONCOLOGY

Journal of the American College of Cardiology, 2024-04, Vol.83 (13), p.2563-2563

2024

Volltextzugriff (PDF)

1 – 25 von 67

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(55)

Publikationsform

Sprache

Englisch
(63)
Italienisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways

Addressing Post-Acute COVID-19 Syndrome in Cancer Patients, from Visceral Obesity and Myosteatosis to Systemic Inflammation: Implications in Cardio-Onco-Metabolism

Screening and management of dyslipidemia in oncologic patients undergoing cardiotoxic therapies: results from an Italian survey

Women at heart: Introducing gender cardio-oncology

Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals

Corrigendum: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways

Case Series: Recovery of Chemotherapy-Related Acute Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable Cardioverter Defibrillator: A Novel Winning Combination in Cardio-Oncology

Portrait of Italian Cardio-Oncology: Results of a Nationwide Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Survey

Corrigendum: Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals

Corrigendum: Cardio-oncology in the COVID Era (Co & Co): The never-ending story

Corrigendum: Portrait of Italian Cardio-Oncology: Results of a Nationwide Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Survey

Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story

Corrigendum: Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story

Arterial Thrombosis in Cancer: Spotlight on the Neglected Vessels

DAPAGLIFLOZIN INCREASES PAMPK AND REDUCES MYOCARDIAL AND RENAL NF-KB EXPRESSION IN PRECLINICAL MODELS OF SHORT-TERM DOXORUBICIN CARDIOTOXICITY THROUGH MYDDOSOME AND INFLAMMASOME PATHWAYS: A HISTOLOGICAL STUDY

BERBERINE ASSOCIATED TO DAPAGLIFLOZIN EXERTS SIGNIFICANT CARDIOPROTECTIVE EFFECTS IN CARDIAC CELLS EXPOSED TO THE HER2-BLOKING AGENT TRASTUZUMAB THROUGH PAMPK ACTIVATION AND REDUCTION IN INTERLEUKIN-6 LEVELS

DAPAGLIFLOZIN REDUCES SYSTEMIC PCSK9 LEVELS IN PRECLINICAL MODELS OF SHORT-TERM DOXORUBICIN CARDIOTOXICITY THROUGH NLRP3 INFLAMMASOME/IL-1β: A FIRST EVIDENCE OF SGLT-2/PCSK9 CROSS-TALK IN CARDIONCOLOGY

Concepts in cardiac oncology

Dapagliflozin associated to sacubitril/valsartan and relationship with cardioprotection in human cardiac cells exposed to doxorubicin and HER2-blocking agents through MyD88, NLRP3 mediated pathways

Abstract 12406: Sglt2i Dapagliflozin Associated to Berberine Reduces Cardiac Cell Apoptosis and Necrosis During Exposure to Her-2 Blocking Agents Through Induction of Pampk and Reduction of Inflammasome, Il-6, Methylglyoxal and Leukotrienes-B4 Levels

Abstract 12402: Sacubitril-Valsartan Increases Pampk and Reduces Inflammasome, Myddosome, Il-6 and Galectin-3 Levels in Short-Term Doxorubicin-Treated Mice Improving Longitudinal Strain and Ejection Fraction

Abstract 12401: Short-term Pdl-1 and Ctla-4 Blocking Agent Therapy Reduces Myocardial Pampk and Il-10 Levels, Increases Vascular Nf-kb Expression and Serum Il-1 / Il-6 Levels

Abstract 10603: Dapagliflozin Increases Ampk, Reduces Fibrosis/Hypertrophy and Nlrp-3, Il-6 and Galectin-3 Levels in Short-Term Doxorubicin-Treated Mice Improving Cardiac Function

COMBINATORIAL IMMUNE CHECKPOINT BLOCKADE INCREASES MYOCARDIAL SECRETION OF H-FABP, NT-PRO-BNP, NLRP-3 INFLAMMASOME, INTERLEUKIN-1β AND INTERLEUKIN-6: BIOCHEMICAL IMPLICATIONS IN CARDIO-IMMUNO-ONCOLOGY

FRUCTOSE EXACERBATES ANTHRACYCLINE AND HER-2 BLOCKING AGENT MEDIATED CARDIOTOXICITY THROUGH NLRP3 AND MYD88 MEDIATED PATHWAYS: NEW ROLES OF SWEETENERS IN CARDIO-ONCOLOGY

Suchergebnisse filtern